<DOC>
	<DOC>NCT01385592</DOC>
	<brief_summary>This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Outpatients with Parkinson's disease (PD), treated with LDopa, experiencing dyskinesias for at least three months Outpatients who are on a stable antiparkinsonian treatment regimen for at least four weeks Surgical treatment for PD Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated) Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Parkinson Disease</keyword>
	<keyword>L-dopa</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Dyskinesia</keyword>
	<keyword>Anti-Dyskinesia Agents</keyword>
</DOC>